Mortality associated with breast cancer is attributable to aggressive metastasis, to which TNFα plays a central orchestrating role. TNFα acts on breast tumor TNF receptors evoking the release of chemotactic proteins (e.g. MCP-1/CCL2). These proteins direct inward infiltration/migration of tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), T-regulatory cells (Tregs), T helper IL-17-producing cells (Th17s), metastasis-associated macrophages (MAMs) and cancer-associated fibroblasts (CAFs). Tumor embedded infiltrates collectively enable immune evasion, tumor growth, angiogenesis, and metastasis. In the current study, we investigate the potential of apigenin, a known anti-inflammatory constituent of parsley, to downregulate TNFα mediated release of chemokines from human triple-negative cells (MDA-MB-231 cells). The results show that TNFα stimulation leads to large rise of CCL2, granulocyte macrophage colony-stimulating factor (GMCSF), IL-1α and IL-6, all suppressed by apigenin. While many aspects of the transcriptome for NFkB signaling were evaluated, the data show signaling patterns associated with CCL2 were blocked by apigenin and mediated through suppressed mRNA and protein synthesis of IKBKe. Moreover, the data show that the attenuation of CCL2 by apigenin in the presence TNFα paralleled the suppression of phosphorylated extracellular signal-regulated kinase 1 (ERK 1/ 2). In summary, the obtained findings suggest that there exists a TNFα evoked release of CCL2 and other LSP recruiting cytokines from human breast cancer cells, which can be attenuated by apigenin.
Introduction
Breast cancer is a leading cause of death in women worldwide, despite medical advances in surgical techniques, radiation and chemotherapy. There is a continued need to identify preventive and adjunctive chemosensitization agents in the management of breast cancer. Apigenin (4',5,7-trihydroxyflavone) is naturally occurring bioactive compound (NOBC) found in parsley, garlic, and celery. The biological relevance of apigenin in management of breast cancer is evidenced by the growing pool of research (in vitro and xenograft tumor models) demonstrating its capacity to PLOS ONE | https://doi.org/10.1371/journal.pone.0175558 April 25, 2017 1 / 17 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
inhibit tumor promoting enzymes [1, 2] , overcome chemoresistance [3, 4] and/or multi-drug resistance [5] , prevent angiogenesis [6] metastasis and lessen the growth of aggressive breast cancers [7] . There is also a plethora of research showing apigenin as a cytostatic agent with capacity to attenuate clonogenic survival in a wide range of breast cancer cells; MDA-MB-231 [8] , SKBR3 [9, 10] , Hs578T, MCF-7 [11] , MDA-MB-453 [12] , MDA-MB-468 Cells [13, 14] , T47D [15] and BT-474 Cells [16] . Biological targets of apigenin relevant to tumor potential are known to involve MAPK/NFkappaB, phospho-JAK1/ STAT3 signaling [17] , VEGF, aromatase, proteasomal processes, fatty acid synthase [18] [19] [20] [21] and the Fas-associated protein with death domain (FADD) [22] . Despite surmounting evidentiary support for apigenin in tumor suppression, there is lack of research regarding its influence on the tumor microenvironment in response to pro-inflammatory cytokines, specifically TNFα. TNFα is present in high concentrations throughout the breast tumor/ stroma milieu, and upon activation of TNFα receptors, can trigger a powerful perpetual cascade of NF-κB activation [23, 24] . epithelial-to-mesenchymal transition [25] and sustained release of diverse chemokines (i.e., CCL2/CCL5) [26] . Chemokines in turn ultimately trigger inward migration of a large number of leukocyte sub-populations (LSPs) bearing CCR2 / CCR5 receptors that embed into the tumor, and further drive tumor aggression and stem cell survival. [ 
Results
A basic cell viability in MDA-MB-231 cells was performed to establish appropriate non-lethal working concentrations of apigenin and TNFα ( Fig 1A) and (Fig 1B) , respectively. Based on these baseline studies, we chose the concentrations of 40μM of apigenin and 40ng/ml of TNFα to carry out all subsequent studies. A semiquantitative analysis was performed to study the cytokine release pattern, in the presence of TNFα and +/-apigenin, using sandwich-based protein arrays from RayBiotech (Norcross, GA, USA). The data obtained show that TNFα caused significant upregulation of few specific cytokines. These cytokines included GM-CSF, CCL2, IL-1α, IL-6 (Fig 2A-2D ) IL-8 and GRO CXCL1/CXCL2/CXCL3 a/b/g (Fig 3A-3D) , some of which were downregulated by apigenin and subject to further validation by ELISA assays. First, the densitometry array values (reflected by INT/MM2) are shown for the effect of apigenin on TNFα mediated release of GM-CSF (Fig 4A) , IL-6 (Fig 4B) , CCL2 and IL-1α ( Fig  4C) . Results were then validated by independent ELISA, where the data paralleled between the findings in the arrays for both CCL2 and IL-1α (Fig 5A and 5B) .
To elucidate potential signaling changes associated with these findings, which were occurring at the transcriptome level, RT-PCR NF-κB arrays were conducted using Signaling Pathway H96 Predesigned 96-well panel for use with SYBR1 Green.CAT Number: 10025558. Biorad (Hercules, CA, USA). The data show a lack of significant changes in all mRNAs involved with NF-κB transcriptome pathway, where IL-1α shows a distinct but non-significant change ( Fig 6A and 6B and Table 1 ). The lack of data as reflected by this RT-PCR NF-κB array was surprising, but a limitation to this array was the absence of IKBK-epsilon which plays a pivotal role in driving tumor malignancy in both TNBC [39] and receptor positive breast cancer cells [40] . Therefore, in the next study, we investigate changes in IKBK-epsilon transcription determined by RT-PCR ( Fig 7A) and protein expression using Western blot (Fig 7B) . These findings validate IKBK-epsilon to be the major proponent of NF-κB signaling control involved with TNF-α mediated rise in CCL2 release and its reduction by apigenin. In the next study, we demonstrate additional influential effects of MAPK signaling on TNF-α mediated CCL2 release, focusing on changes in phospho-ERK protein, also downregulated by apigenin (Fig 8) . These findings show that apigenin can alter TNF-α mediated breast cancer signaling pathways that control the release of CCL2, which in part involve IKBK-epsilon, and ERK, both essential biological events required for TAM infiltration and recruitment into solid breast tumor tissue.
Discussion
The findings in this study describe another anti-cancer property of apigenin to add to the arsenal of existing research having shown its ability to attenuate tumor promoting enzymes [1, 2] , prevent chemoresistance/multi-drug resistance [3] [4] [5] , halt angiogenesis [6] lessening VEGF, inhibiting aromatase, proteasomal processes and fatty acid synthase, [18] [19] [20] [21] and an overall reduction in proliferation, migration, and invasion of aggressive breast cancer [7] . Here we demonstrate the ability of apigenin to block TNFα mediated release of pro-inflammatory cytokines which are themselves responsible for inward migration of leukocytes that drive tumor growth, metastatic invasion [27], stem cell survival and immune evasion [23] . . While all LSP subtypes enable a tumor permissive and the evasive immune environment [41] , independently, each LSP can confer a unique independent effect. For example, the arrival of MDSCs leads to potent immunosuppression by disabling the normal function of T and NK cells [42] . Whereas, the arrival of TANS perpetuates a sustained release of CCL2, GM-CSF, CCL17 which correspond to elevated tumor size, microvascular invasion and inward migratory activity of the macrophages and Tregs [43] . Reported results on Tregs indicate a direct role in suppression of antitumor immunity by attenuating the Tcell-mediated tumor cell killing [33] and secreting TGF-beta1 [44, 45] . Meanwhile, the collective activity of TANS and MDSCS both yield the perpetual release of CCL2 and M-CSF fostering synergistic infiltration of TAMS. TAMS, upon arrival, can then lead to even more release of promoting cytokines: TGF-beta, MMPs, VEGF, CM/M-CSF, CCL 17, IL-13 and CCL2 which secure pro-angiogenic tumor processes [46] . In aggressive malignancies, metastatic MAMs arrive at secondary sites and in turn recruit inflammatory CCR2 bearing monocytes by CCL2, which in themselves release CCL3 and express CCR1, amplifying tumor potential [47] . LSP tumor infiltration is a vastly complex topic, yet all of these studies suggest the importance of controlling the chemokines produced and released by tumor tissue.
The current study shows that apigenin can downregulate TNFα mediated release of CCL2, largely attributable to its ability to downregulate IKBKe. https://doi.org/10.1371/journal.pone.0175558.g003 [50] . Likewise, numerous studies show many of these signaling pathways are blocked by apigenin in tumor models [17] in particular NF-kB signaling [51, 52] which controls the downstream release of TGF-b [53] and activity of MMP-9 [54] , themselves involved with TAM/ TANs [55] [56] [57] and Treg recruitment [44, 45] .
The capacity of apigenin to block CCL2 is important because this single event is not only in control of infiltrating/migratory activity of CAFs, TAMS, TANS, and MSCs into the tumor environment but enables its perpetual ongoing accelerated release of CCL2, CXCL8, CCL5, mediated by through NF-kB signaling [24] . There is sufficient evidence to show that initial release of chemokines such as CCL2, GM-CSF [58] mark a potentially irreversible turning point for tumor infiltration, immunological evasion, and tumor immune support [29, 59, 60] . Natural plant-derived chemicals that can downregulate CCL2 or act as CCR2 receptor antagonists [61] such as luteolin [62] esculetin [63] or EGCG [64, 65] typically result in impaired migration, less proclivity for metastasis [66] enabling greater efficacy of immunotherapies and chemotherapy drugs [65] .
In summary, these findings show that apigenin can block TNFα mediated release of CCL2 in a TNBC cell line. While the experimental evidence for the therapeutic application of apigenin in cancer treatment is growing, human clinical trials are lacking [67] . Future studies will be required to determine if apigenin can be used clinically to establish long-term remission in cancer patients.
Materials and methods

Cell line, chemicals, and reagents
Triple-negative human breast tumor (MDA-MB-231) cells were obtained from the American Type Culture Collection (Rockville, MD, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS) and penicillin/streptomycin were all obtained from Invitrogen (Carlsbad, CA, USA). Recombinant human TNFα was purchased from RayBiotech (RayBiotech Inc., Norcross, GA, USA). Apigenin was purchased from Abcam (Cambridge, United Kingdom).
Cell culture
MDA-MB-231 cells were cultured in 75 cm2 or 175 cm2 flasks containing DMEM supplemented with 10% FBS and 1% 10,000 U/ml penicillin G sodium/10,000 μg/ml streptomycin sulfate. Cells were grown at 37˚C with humidified 95% air and 5% CO2.
Cell viability assay
Alamar Blue cell viability assay was used to determine cytotoxicity. Viable cells are capable of reducing resazurin to resorufin, resulting in fluorescence changes. Briefly, 96-well plates were seeded with MDA-MB-231 cells at a density of 5×104cells/100 μl/well. Cells were treated without or with either apigenin (10 μM, 20 μM, 30 μM, 40 μM 50 uM, 60 μM 70 μM 80 μM 90 μM 100 μM) or TNFα (0.1, 1, 10, 20, 40, 80, 100 ng/ml) for 24 h at 37˚C, 5% CO2. Alamar blue (0.1 mg/ml in HBSS) was added at 15% v/v to each well and incubated for 6-8 hrs. Quantitative analysis of dye conversion was measured on a microplate fluorometer-Model 7620-version 5.02 Human adipokine array
Sandwich-based arrays purchased from RayBiotech (Norcross, GA, USA) consist of membranes with 62 different proteins in duplicate. Each experiment was carried out by manufacturer's instructions. Briefly, antibody-coated array membranes were treated with 1 ml of medium from resting, apigenin-treated (40 μM), TNFα-treated (40 ng) and co-treated cells and incubated overnight at 4˚C on a rocker/shaker. The medium was decanted, the membranes were washed with wash buffer and then incubated with 1 ml biotin-conjugated antibodies (overnight 4˚C). The mixture of biotin-conjugated antibodies was removed, and membranes were incubated with horseradish peroxidase-conjugated streptavidin (2 h). After a final wash, membrane intensity was acquired using chemiluminescence and analyzed using Quantity One software (Biorad Laboratories, Hercules. CA, US). Densities were calculated by subtracting blanks values from each array, then calculating all values as a percentage of the positive control spots on each membrane multiplied by an arbitrary averaged control values across all arrays in one individual test set. The data are represented as Density (Intensity (INT)/MM2).
CCL2 and IL-1α detection by ELISA
Supernatants from resting and stimulated (24 h) MDA-MB-231 cells were collected and centrifuged at 100× g for 5 min at 4˚C. Specific ELISAs were performed using MCP-1/ CCL2 ELISA kits (RayBiotech) following the manufacturer's instructions. Briefly, 100 μl of supernatants from samples and standards were added to 96-well plates pre-coated with capture antibody.
After incubation, 100 μl of prepared biotinylated antibody mixture was added to each well. After one hour, the mixture was decanted, and 100 μl streptavidin solution was placed in each well and incubated. Substrate reagent (100 μl) was then added to each well followed by the addition of 50 μl stop solution 30 min later. The plate was read at 450 nm using UV microplate reader.
RT-PCR and RT-RCR NF-kB signaling pathway
MDA-MB-231 cells were lysed with 1 ml Trizol reagent. Chloroform (0.2 ml) was added samples were vortexed, incubated at 15-30˚C for 2-3 min and centrifuged at 10,000 x g for 15 min. at 2-8˚C. The aqueous phase was transferred to a fresh tube, and the RNA precipitated by mixing 0.5 ml isopropyl alcohol. RNA was extracted and subject to iScript advanced reverse transcriptase (RT) to the reaction. The reverse transcription was performed for 30 min at 42˚C and RT inactivation for 5 min. at 85˚C. PCR reaction. The following components were mixed in a 0.5 ml PCR tube: 5.0 μl cDNA product, 10 μl Ss Advanced Universal SYBR Green, 1.0 μl primer and 4 μl water. PCR was performed with 39 cycles of denaturation: 15 sec. at 95˚C; annealing: 30 sec. at 60˚C; and extension 60 sec. at 72˚C using Bio-Rad CFX96 Real-Time System (Hercules, Ca, USA). cDNA synthesis and Real-Time PCR was performed using iScript Advanced synthesis kit / SsAdvanced Universal SYBR 1 Green according to manufacturer's instructions. RT-PCR for IKBKe was run normalized to GAPDH mRNA, and the normalized values for the NF-kB Signaling array are as specified in Fig 6A. The array used was the transcription-NF-kB Signaling Pathway H96 Predesigned 96-well panel for use with SYBR1 Green (Bio-Rad, Hercules, CA). 
Western blot ERK1/2 and IKBKe
Total cell protein concentrations from MDA-MB-231 cells treated with apigenin, with and without TNFα co-treatment, was determined using a modified Bio-Rad "DC" protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Cell lysates were separated by electrophoresis on 10% SDS-polyacrylamide gels and then transferred to Immobilon-P PVDF membranes. Blots were blocked at 4˚C overnight in 5% bovine serum albumin (Sigma, St. Louis, MO, USA) in Tris-buffered saline with 0.05% Tween 20 in PBS (PBST) and then incubated overnight at 4˚C with mouse anti-human ERK1/2 and IKBKe affinity purified antibody (Cell Signaling, Danvers, Ma, USA). Membranes were washed with PBST and incubated overnight with anti-goat IgG-horseradish peroxidase (Santa Cruz Biotechnology, CA) in PBST overnight at 4˚C. Protein loading was monitored in each gel lane by probing the membranes with anti-GAPDH antibodies (Santa Cruz, Ca, USA). Immunoblot images were obtained using a Flour-S Max Multimager (Bio-Rad Laboratories, Hercules, CA). Lane density data was acquired with Quantity One Software (Bio-Rad Laboratories, Hercules, and CA).
Statistical analysis
Statistical analysis was performed using GraphPad Prism (version 3.0; GraphPad Software Inc. San Diego, CA, USA) with the significance of the difference between the groups assessed using a one-way ANOVA, followed by Tukey post hoc means comparison test, two-way ANOVA or Student's t-test.
Author Contributions
Conceptualization: DB KS.
Data curation: DB NR EM.
Formal analysis: DB NR EM.
Funding acquisition: KS.
Investigation: DB NR EM KS.
Methodology: DB KS.
Project administration: KS.
Resources: DB NR EM KS.
Software: DB NR EM KS.
Supervision: KS.
Validation: DB NR EM. 
